metricas
covid
Buscar en
European Journal of Psychiatry
Toda la web
Inicio European Journal of Psychiatry Sex differences in changes in prolactin levels and sexual function after switchi...
Información de la revista
Vol. 38. Núm. 3.
(julio - septiembre 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 38. Núm. 3.
(julio - septiembre 2024)
Original article
Sex differences in changes in prolactin levels and sexual function after switching from risperidone to paliperidone palmitate in schizophrenia
Meritxell Tosta,b, Juan David Barberoa, Itziar Montalvoa,b,d, Alexandre González-Rodríguezc, Raquel Aguayoa, Aida Álvarezc, Rosa Gabernete, Eduard Izquierdoc, Igor Merodioa, Siddarta Acebilloa, Diego Palaoa,b,d, Javier Labadd,e,
Autor para correspondencia
jlabad@csdm.cat

Corresponding author.
a Department of Mental Health, Parc Taulí Hospital Universitari, I3PT. Sabadell, Barcelona, Spain
b Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, Spain
c Department of Mental Health, Hospital Mútua de Terrassa, Terrassa, Barcelona, Spain
d CIBERSAM. Sabadell, Barcelona, Spain
e Department of Mental Health and Addictions, Consorci Sanitari del Maresme. Mataró, Barcelona, Spain
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Tablas (3)
Table 1. Baseline sociodemographic and clinical variables of 27 patients with schizophrenia who completed follow-up visits.
Table 2. Fixed effects of the linear mixed model exploring longitudinal changes in prolactin concentrations in 27 patients with schizophrenia.
Table 3. Longitudinal changes in continuous variables.
Mostrar másMostrar menos
Abstract
Background and objectives

Hyperprolactinaemia is a significant side effect of antipsychotic medications and may cause sexual dysfunction. Although risperidone and paliperidone can induce prolactin elevation, previous studies suggest that switching from risperidone long-acting injectable (LAI) to paliperidone palmitate (PP) might reduce prolactin concentrations in early psychosis patients. We aimed to evaluate the effect of switching from risperidone to PP on sexual functionality and prolactin levels in patients with schizophrenia.

Methods

We studied 38 patients with schizophrenia who were treated with risperidone (oral or R-LAI) monotherapy at stable doses for at least two months and had an indication to be switched to PP by their psychiatrists. Three assessments were completed: 1) baseline (preswitch), 2) 3 months post-switch, and 3) 6 months post-switch. Prolactin concentrations in plasma were determined. Sexual functioning was assessed with the Arizona Sexual Experience Scale (ASEX). Statistical analyses were conducted in 27 patients who had at least one follow-up visit. Longitudinal changes in prolactin levels and sexual function after switching from risperidone to PP were analysed with linear mixed models. Significance was set at p < 0.05.

Results

Prolactin concentrations were reduced in women after the switch, with a significant time by sex effect (p = 0.035). Antipsychotic doses influenced prolactin levels (p = 0.006), such that higher antipsychotic doses were associated with higher prolactin concentrations. No significant differences were found in ASEX total scores at 6 months after the switch.

Conclusions

In patients with schizophrenia, switching from risperidone to PP was associated with a reduction in prolactin concentrations in women but not men.

Keywords:
Prolactin
Risperidone
Paliperidone palmitate
Sexual dysfunction
Sex differences

Artículo

Opciones para acceder a los textos completos de la publicación European Journal of Psychiatry
Suscriptor
Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".
Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 19,34 €

Comprar ahora
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos